Once again demonstrating a strong commitment to innovation in the biomedical field, InnoModels Biotechnology introduces the iHuPBMC-MHC/KO, an innovative product for immunological research. iHuPBMC-MHC/KO is a forward-thinking product that provides scientists with groundbreaking tools to advance immunological research and expand our understanding of the immune system.
Technical Breakthrough of iHuPBMC-MHC/KO
iHuPBMC-MHC/KO is a model based on Human Peripheral Blood Mononuclear Cells (iHuPBMC) with a special focus on Major Histocompatibility Complex (MHC) Knockout (KO). The following are its major technological breakthroughs:
Main Features and Advantages
1. MHC knockout technology:
iHuPBMC-MHC/KO uses advanced gene editing technology to successfully realize MHC gene knockout. This allows researchers to simulate the effects of MHC deletion on the immune system under specific conditions, providing a completely new perspective for immunological research.
2. Research on the mechanism of immune tolerance and rejection:
Modeling provides an ideal platform for studying immune tolerance and rejection mechanisms. Through MHC knockdown, how the immune system responds to the missing MHC can be explored in depth, providing new ideas for organ transplantation and autoimmune disease research.
3. Personalized immunotherapy development:
iHuPBMC-MHC/KO is expected to support the development of personalized immunotherapy. By mimicking different MHC genotypes, researchers can better understand the immune system response to individualized therapies.

Scientific applications and future perspectives
1. Immunomodulatory disease therapy:
iHuPBMC-MHC/KO provides a new research tool for the study of immune-modulated disease therapy, which is expected to provide a scientific basis for the design of therapeutic strategies for inflammatory diseases and autoimmune diseases.
2. organ transplantation research:
The model provides unprecedented opportunities for the study of immune rejection in organ transplantation, which is expected to promote innovative development in the field of organ transplantation.
3. Future Innovation Direction:
InnoModels Biotechnology will continue to invest in research and development to explore new areas of immunology and clinical applications of iHuPBMC-MHC/KO, and to promote greater breakthroughs in immunology research.
Conclusion
The launch of iHuPBMC-MHC/KO marks an outstanding innovation in the field of immunology by InnoModels Biotechnology. The unique nature of this product provides scientists with a powerful tool that is expected to drive research progress in the field of immunology and offer more possibilities for future immunotherapy and disease treatment.